Study of two immunotherapy drugs for rectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with newly diagnosed rectal adenocarcinoma that has not spread. The goal is to see if this treatment can shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal adenocarcinoma (a type of rectal cancer) confirmed by biopsy.
- Tumor is at or below 15 cm from the anal opening by colonoscopy and is stage cT3/cT4 N0 or cT(any) N1/2 (locally advanced but not spread to distant organs).
- No signs of cancer spread to other parts of the body (no distant metastases).
- Your tumor shows intact mismatch repair proteins (called pMMR or MSS), meaning it is not the MSI-H type.
- You have not had prior radiation, chemotherapy, or surgery for rectal cancer.
- You are age 18 or older and have a good performance status (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) given before surgery for early-stage rectal cancer that is MSS/pMMR. The goal is to see if this treatment can shrink the tumor and improve outcomes compared to standard care.
This trial tests a combination of two immunotherapy drugs (anti-PD-1 and anti-CTLA-4) for locally advanced rectal cancer that hasn't spread far. The goal is to see if this treatment can help shrink tumors and improve outcomes before surgery.
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
This trial tests a combination of chemotherapy (FOLFOX) and two immunotherapies (botensilimab and balstilimab) before surgery for patients with localized rectal cancer. It aims to see if adding immunotherapy helps shrink the tumor and improve outcomes.
This trial tests two new immunotherapy drugs (botensilimab and balstilimab) given after standard treatment for stage II or III colorectal cancer. The drugs are designed to boost your immune system to prevent cancer from coming back, especially if cancer cells are detected in your blood.
Hear when a new Locally Advanced Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.